Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA - Eisenberger, M; Hardy-Bessard, A-C; Kim, CS (J Clin Oncol Off J Am Soc Clin Oncol, 2017)
et al.